My guess is the stock is reacting postively to newly announced plans for a registered clinical trial in MDS. The data must be outstanding and I hope we see it soon. The fact that sapa can produce a median survival of 8 to 9 months after failure on HMA agents is really amazing, and there are no currently approved treatments. A study by the M.D. Anderson Cancer Center was published in an abstract in 2010 showing a median survival of 4.3 months for patients with myelodisplastic syndrome after failure of decitabine therapy in 87 patients. You can google and find the abstract on NCBI.